SCHEMBL3925199

SCHEMBL3925199

O=C(O)c1ccn2c(-c3cccc(Cl)c3)cnc2c1.[Na]

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.69
KDR P35968 8/20 0.57
FGFR3 P22607 6/20 0.57
BACE1 P56817 1/20 0.49
DYRK3 O43781 1/20 0.49
CCNT1 O60563 1/20 0.49
CCNA2 P20248 1/20 0.49
CDK2 P24941 1/20 0.49
CDK9 P50750 1/20 0.49
CDK5 Q00535 1/20 0.49
DYRK1A Q13627 1/20 0.49
CDK5R1 Q15078 1/20 0.49
DYRK2 Q92630 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
EGLN1 Q9GZT9 1/20 0.46
RIPK2 O43353 1/20 0.45
LYN P07948 1/20 0.45
MAP4K4 O95819 1/20 0.44
AURKA O14965 1/20 0.43
CSF1R P07333 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3923867 0.99 HPGD (0.70) HPGDKDRFGFR3BACE1DYRK3
SCHEMBL3925188 0.97 HPGD (0.69) HPGDKDRFGFR3BACE1DYRK3
SCHEMBL3925191 0.86 HPGD (0.67) HPGDKDRFGFR3BACE1DYRK3
SCHEMBL24329732 0.84 HPGD (0.65) HPGDKDRFGFR3BACE1DYRK3
SCHEMBL23675321 0.82 HPGD (1.00) HPGDKDRFGFR3NPC1RAB9A
SCHEMBL23685645 0.79 FGFR3 (0.53) HPGDKDRFGFR3
SCHEMBL3920430 0.79 HPGD (0.47) HPGDKDRFGFR3NPC1RAB9A
SCHEMBL3022584 0.78 KDR (0.69) HPGDKDRFGFR3DYRK1ARIPK2
SCHEMBL22588131 0.77 HPGD (0.45) HPGDKDRFGFR3EGLN1MAP4K4
SCHEMBL25250708 0.76 EGLN2 (0.56) HPGDKDRMAP4K4FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563797-B2 Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands Forest Laboratories Holding Limited (BM) 2009-07-21 US disclosed
US-20080058350-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058350-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES CNR2, CNR1, P2RY4 HPGD 1090/4885KDR 814/4885FGFR3 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.